hereditary angioedema hae epidemiology forecast
DelveInsight’s ‘Hereditary Angioedema (HAE)- Epidemiology Forecast–2034’ report delivers an in-depth understanding of HAE, historical and forecasted epidemiology as well as HAE trends in the United States, the EU5 (Germany, France, Italy, Spain) and the United Kingdom, Japan, and China.
Geographies Covered
- The United States
- The EU4 (Germany, France, Italy, Spain) and the United Kingdom
- Japan
- China
Study Period: 2021-2034
Hereditary Angioedema (HAE) Disease Understanding
Hereditary Angioedema (HAE) is a rare genetic disorder that predisposes an individual to develop vasogenic edema. This genetic disorder is caused by the deficiency in functional C1 inhibitor (C1-INH) that results in recurrent attacks of localized subcutaneous or mucosal edema, most commonly affecting the skin, intestines, upper respiratory tract, and oropharynx.
Clinical manifestations include abrupt onset swelling around the eyes, face, and extremities; pain abdomen (because of bowel edema) and laryngeal edema leading to hoarseness of voice, breathing difficulty, and occasionally death.
Hereditary Angioedema (HAE) Diagnosis
Early detection and diagnosis of HAE before the onset of clinical symptoms are critical for appropriate treatment, preserving patients’ quality of life, and even the first attack of laryngeal edema can be fatal.
Diagnosis is made through a careful evaluation of clinical symptoms and family history and is confirmed using laboratory testing. Clinical symptoms of recurrent abdominal pain or edema without associated urticaria should prompt suspicion of HAE, particularly in patients with a positive family history.
Continued in the report…..
Hereditary Angioedema (HAE) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Diagnosed Prevalent Cases of Hereditary Angioedema (HAE), Type-specific Diagnosed Prevalent Cases of Hereditary Angioedema (HAE), Gender-specific Diagnosed Prevalent Cases of Hereditary Angioedema (HAE), and Age-specific Diagnosed Prevalent Cases of Hereditary Angioedema (HAE) in the 7MM+China covering the United States, the EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, Japan, and China from 2021 to 2034.
Key Findings
- Total diagnosed prevalent cases of HAE in the 7MM+China was found to be 14,375 approximately in 2021, which might increase by the end of 2034. These cases are expected to increase at a considerable CAGR during study period (2021-2034).
- Among 7MM+China, the United States has the highest diagnosed prevalent cases of HAE with 7,614 cases in 2021.
- Among the European countries, the UK had the highest diagnosed prevalent population of HAE, with approximately 1,348 cases, followed by Germany, which had 1,266 diagnosed prevalent population in 2021. On the other hand, Spain and Italy had the lowest and equal number of diagnosed prevalent population as approximately 942 cases in 2021.
- The type-specific diagnosed prevalent cases of HAE is categorized into Type I, Type II, and HAE with normal C1-INH (Type III). Among these, Type I HAE accounted for the highest cases in the 7MM+China as estimated to be 12,345 in 2021.
- The diagnosed prevalent cases of HAE in the 7MM+China varied according to gender, with prevalent cases higher in females than males.
- Based on age segmented as =17 years, 17–65 years, and =65 years, a higher percentage of diagnosed prevalent cases were observed in the age group 17–65 years in all the 7MM+China countries were approximately 11,312 in 2021, which anticipated to rise during the forecasted period (2022-2034).
- Japan accounted for approximately 462 diagnosed prevalent cases of HAE in the year 2021 which are expected to decrease during the forecasted period (2022-2034).
- The total diagnosed prevalent cases of HAE in the China is anticipated to rise from estimated 563 cases in 2021 at a considerable CAGR for the study period (2021-2034).
Scope of the Report
- The report covers the descriptive overview of HAE, explaining its symptoms, etiology, pathogenesis, and various diagnostic approaches.
- The report provides insight into the 7MM+China historical and forecasted patient pool covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, Japan, and China.
- The report assesses the disease risk and burden of HAE.
- The report helps to recognize the growth opportunities in the 7MM+China with respect to the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM+China diagnosed prevalent cases of Hereditary Angioedema (HAE), type-specific diagnosed prevalent cases of Hereditary Angioedema (HAE), gender-specific diagnosed prevalent cases of Hereditary Angioedema (HAE), and age-specific diagnosed prevalent cases of Hereditary Angioedema (HAE).
Report Highlights
- 10-year forecast of Hereditary Angioedema (HAE)
- The 7MM+China Coverage
- Total diagnosed prevalent cases of Hereditary Angioedema (HAE)
- Type-specific diagnosed prevalent cases of Hereditary Angioedema (HAE)
- Gender-specific diagnosed prevalent cases of Hereditary Angioedema (HAE)
- Age-specific diagnosed prevalent cases of Hereditary Angioedema (HAE)
Key Questions Answered
- What are the disease risk and burdens of Hereditary Angioedema (HAE)?
- What is the historical Hereditary Angioedema (HAE) patient pool in the United States, the EU4 (Germany, France, Italy, Spain) and the UK, Japan, and China?
- What would be the forecasted patient pool of Hereditary Angioedema (HAE) at the 7MM+China level?
- What will be the growth opportunities across the 7MM+China concerning the patient population about Hereditary Angioedema (HAE)?
- Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Hereditary Angioedema (HAE) during the forecast period (2025-2034)?
- At what CAGR the population is expected to grow across the 7MM+China during the forecast period (2025-2034)?
Reasons to buy
The Hereditary Angioedema (HAE) report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM+China Hereditary Angioedema (HAE) epidemiology forecast.
- The Hereditary Angioedema (HAE) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The Hereditary Angioedema (HAE) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
Key Assessments
- Patient Segmentation
- Disease Risk and Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population
1. Key Insights
2. Report Introduction
3. Hereditary Angioedema Patient Overview at a Glance
3.1. Patient Share (%) Distribution of HAE in 2021
3.2. Patient Share (%) Distribution of HAE in 2034
4. Executive Summary of Hereditary Angioedema
6. Hereditary Angioedema (HAE): Disease Overview
6.1. Introduction of HAE
6.2. Types of HAE
6.3. Cause of HAE
6.4. Genetics of HAE
6.5. Pathophysiologic and Immunologic Features of HAE
6.5.1. Mechanisms of Edema Formation
6.6. Risk Factors of HAE
6.7. Symptoms of HAE
6.8. Clinical Presentation of HAE
6.9. Diagnosis of HAE
6.9.1. Differential and delayed diagnosis
6.9.2. Diagnostic algorithm
6.9.3. Diagnosis Guidelines
6.9.3.1. US HAEA Medical Advisory Board: Guidelines for the Management of HAE
6.9.3.2. The International World Allergy Organization / European Academy of Allergy and Clinical Immunology Guideline for the Management of HAE
6.9.3.3. The Japanese Association for Complement Research: Guideline for HAE
7. Epidemiology and Patient Population of HAE
7.1. Key Findings
7.2. Methodology of Epidemiology
7.3. Assumptions and Rationale: The 7MM + China
7.4. Total Diagnosed Prevalent Cases of HAE in 7MM + China
7.5. The United States
7.5.1. Total Diagnosed Prevalent Cases of HAE in the US
7.5.2. Type-specific Diagnosed Prevalent Cases of HAE in the US
7.5.3. Gender-specific Diagnosed Prevalent Cases of HAE in the US
7.5.4. Age-specific Diagnosed Prevalent Cases of HAE in the US
7.6. EU-4 Countries and the UK
7.6.1. Germany
7.6.1.1. Total Diagnosed Prevalent Population of HAE
7.6.1.2. Type-specific Diagnosed Prevalent Cases of HAE
7.6.1.3. Gender-Specific Diagnosed Prevalent Population of HAE
7.6.1.4. Age-specific Diagnosed Prevalent Population of HAE
7.6.2. France
7.6.2.1. Total Diagnosed Prevalent Population of HAE
7.6.2.2. Type-specific Diagnosed Prevalent Cases of HAE
7.6.2.3. Gender-Specific Diagnosed Prevalent Population of HAE
7.6.2.4. Age-specific Diagnosed Prevalent Population of HAE
7.6.3. Italy
7.6.3.1. Total Diagnosed Prevalent Population of HAE
7.6.3.2. Type-specific Diagnosed Prevalent Cases of HAE
7.6.3.3. Gender-Specific Diagnosed Prevalent Population of HAE
7.6.3.4. Age-specific Diagnosed Prevalent Population of HAE
7.6.4. Spain
7.6.4.1. Total Diagnosed Prevalent Population of HAE
7.6.4.2. Type-specific Diagnosed Prevalent Cases of HAE
7.6.4.3. Gender-Specific Diagnosed Prevalent Population of HAE
7.6.4.4. Age-specific Diagnosed Prevalent Population of HAE
7.6.4. The UK
7.6.4.1. Total Diagnosed Prevalent Population of HAE
7.6.4.2. Type-specific Diagnosed Prevalent Cases of HAE
7.6.4.3. Gender-Specific Diagnosed Prevalent Population of HAE
7.6.4.4. Age-specific Diagnosed Prevalent Population of HAE
7.7. Japan Epidemiology
7.7.1. Total Diagnosed Prevalent Cases of HAE in Japan
7.7.2. Type-specific Diagnosed Prevalent Cases of HAE in Japan
7.7.3. Gender-specific Diagnosed Prevalent Cases of HAE in Japan
7.7.4. Age-specific Diagnosed Prevalent Cases of HAE in Japan
7.9. China Epidemiology
7.9.1. Total Diagnosed Prevalent Cases of HAE in China
7.9.2. Type-specific Diagnosed Prevalent Cases of HAE in China
7.9.3. Gender-specific Diagnosed Prevalent Cases of HAE in China
7.9.4. Age-specific Diagnosed Prevalent Cases of HAE in China
8. Patient Journey
9. Key Opinion Leaders’ Views
10. Appendix
10.1. Bibliography
10.2. Acronyms and Abbreviations
10.3. Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight
List of Tables:
List of Table
Table 1: Summary of HAE Epidemiology (2021-2034)
Table 2: A Comprehensive Table of HAE Types
Table 3: Types of HAE
Table 4: Summary of the Mutations Described in F12, Plasminogen (PLG), and Angiopoietin (ANGPT1) Genes Resulting in HAE
Table 5: Clinical Features in the Differential Diagnosis of Angioedema
Table 6: US HAEA Medical Advisory Board Guidelines for Diagnosis of HAE
Table 7: Evidence Grades
Table 8: Total diagnosed Prevalent Cases of HAE in 7MM (2021-2034)
Table 9: Total Diagnosed Prevalent Cases of HAE in the US (2021-2034)
Table 10: Type-specific Diagnosed Prevalent Cases of HAE in the US (2021-2034)
Table 11: Gender-specific Diagnosed Prevalent Cases of HAE in the US (2021-2034)
Table 12: Age-specific Diagnosed Prevalent Cases of HAE in the US (2021-2034)
Table 13: Total Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2021-2034)
Table 14: Total Diagnosed Prevalent Cases of HAE in Germany (2021-2034)
Table 15: Total Diagnosed Prevalent Cases of HAE in France (2021-2034)
Table 16: Total Diagnosed Prevalent Cases of HAE in Italy (2021-2034)
Table 17: Total Diagnosed Prevalent Cases of HAE in Spain (2021-2034)
Table 18: Total Diagnosed Prevalent Cases of HAE in the UK (2021-2034)
Table 19: Type-specific Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2021-2034)
Table 20: Type-specific Diagnosed Prevalent Cases of HAE in Germany (2021-2034)
Table 21: Type-specific Diagnosed Prevalent Cases of HAE in France (2021-2034)
Table 22: Type-specific Diagnosed Prevalent Cases of HAE in Italy (2021-2034)
Table 23: Type-specific Diagnosed Prevalent Cases of HAE in Spain (2021-2034)
Table 24: Type-specific Diagnosed Prevalent Cases of HAE in the UK (2021-2034)
Table 25: Gender-specific Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2021-2034)
Table 26: Gender-specific Diagnosed Prevalent Cases of HAE in Germany (2021-2034)
Table 27: Gender-specific Diagnosed Prevalent Cases of HAE in France (2021-2034)
Table 28: Gender-specific Diagnosed Prevalent Cases of HAE in Italy (2021-2034)
Table 29: Gender-specific Diagnosed Prevalent Cases of HAE in Spain (2021-2034)
Table 30: Gender-specific Diagnosed Prevalent Cases of HAE in the UK (2021-2034)
Table 31: Age-specific Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2021-2034)
Table 32: Age-specific Diagnosed Prevalent Cases of HAE in Germany (2021-2034)
Table 33: Age-specific Diagnosed Prevalent Cases of HAE in France (2021-2034)
Table 34: Age-specific Diagnosed Prevalent Cases of HAE in Italy (2021-2034)
Table 35: Age-specific Diagnosed Prevalent Cases of HAE in Spain (2021-2034)
Table 36: Age-specific Diagnosed Prevalent Cases of HAE in the UK (2021-2034)
Table 37: Total Diagnosed Prevalent Cases of HAE in Japan (2021-2034)
Table 38: Type-specific Diagnosed Prevalent Cases of HAE in Japan (2021-2034)
Table 39: Gender-specific Diagnosed Prevalent Cases of HAE in Japan (2021-2034)
Table 40: Age-specific Diagnosed Prevalent Cases of HAE in Japan (2021-2034)
Table 41: Total Diagnosed Prevalent Cases of HAE in China (2021-2034)
Table 42: Type-specific Diagnosed Prevalent Cases of HAE in China (2021-2034)
Table 43: Gender-specific Diagnosed Prevalent Cases of HAE in China (2021-2034)
Table 44: Age-specific Diagnosed Prevalent Cases of HAE in China (2021-2034)
List of Figures:
List of Figures
Figure 1: Hereditary Angioedema
Figure 2: Differentiation Between Types of HAE
Figure 3: Autosomal Dominant Disease
Figure 4: Summary of the Genetic Defects Leading to the Phenotype of HAE
Figure 5: Various Mutations Reported in the SERPING1 Gene
Figure 6: Counteracting Influences of Angiopoietin 1 and BK on Vascular Endothelial Cells
Figure 7: C1 Esterase Inhibitor Prevents the Auto-activation of Complement C1
Figure 8: C1 Esterase Inhibitor Inactivates Factors XIIa and XIIf, plasmin, and kallikrein, Preventing BK Production
Figure 9: C1 Esterase Inhibitor Modulates Complement and Contact System Activation; Preventing BK Release
Figure 10: Mechanism of Activation of the Contact System
Figure 11: Dysregulation of Coagulation, Complement, and Contact Cascades in HAE
Figure 12: Kinin Metabolism and the Mutual Interactions Between the Kinin, Complement, Hemostatic and Fibrinolytic Pathways
Figure 13: Risk Factors of HAE
Figure 14: Symptoms of HAE
Figure 15: Diagnostic Algorithm for HAE
Figure 16: Diagnostic Algorithm for Evaluation of a Suspected Case of HAE (HAE With Normal C1 Inhibitor Function Requires Genetic Analysis for Diagnosis)
Figure 17: Total Diagnosed Prevalent Cases of HAE in 7MM + China (2021-2034)
Figure 18: Total Diagnosed Prevalent Cases of HAE in the US (2021-2034)
Figure 19: Type-specific Diagnosed Prevalent Cases of HAE in the US (2021-2034)
Figure 20: Gender-specific Diagnosed Prevalent Cases of HAE in the US (2021-2034)
Figure 21: Age-specific Diagnosed Prevalent Cases of HAE in the US (2021-2034)
Figure 22: Type-specific Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2021-2034)
Figure 23: Type-specific Diagnosed Prevalent Cases of HAE in Germany (2021-2034)
Figure 24: Type-specific Diagnosed Prevalent Cases of HAE in France (2021-2034)
Figure 25: Type-specific Diagnosed Prevalent Cases of HAE in Italy (2021-2034)
Figure 26: Type-specific Diagnosed Prevalent Cases of HAE in Spain (2021-2034)
Figure 27: Type-specific Diagnosed Prevalent Cases of HAE in the UK (2021-2034)
Figure 28: Gender-specific Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2021-2034)
Figure 29: Gender-specific Diagnosed Prevalent Cases of HAE in Germany (2021-2034)
Figure 30: Gender-specific Diagnosed Prevalent Cases of HAE in France (2021-2034)
Figure 31: Gender-specific Diagnosed Prevalent Cases of HAE in Italy (2021-2034)
Figure 32: Gender-specific Diagnosed Prevalent Cases of HAE in Spain (2021-2034)
Figure 33: Gender-specific Diagnosed Prevalent Cases of HAE in the UK (2021-2034)
Figure 34: Age-specific Diagnosed Prevalent Cases of HAE in EU-4 and the UK (2021-2034)
Figure 35: Age-specific Diagnosed Prevalent Cases of HAE in Germany (2021-2034)
Figure 36: Age-specific Diagnosed Prevalent Cases of HAE in France (2021-2034)
Figure 37: Age-specific Diagnosed Prevalent Cases of HAE in Italy (2021-2034)
Figure 38: Age-specific Diagnosed Prevalent Cases of HAE in Spain (2021-2034)
Figure 39: Age-specific Diagnosed Prevalent Cases of HAE in the UK (2021-2034)
Figure 40: Total Diagnosed Prevalent Cases of HAE in Japan (2021-2034)
Figure 41: Type-specific Diagnosed Prevalent Cases of HAE in Japan (2021-2034)
Figure 42: Gender-specific Diagnosed Prevalent Cases of HAE in Japan (2021-2034)
Figure 43: Age-specific Diagnosed Prevalent Cases of HAE in Japan (2021-2034)
Figure 44: Total Diagnosed Prevalent Cases of HAE in China (2021-2034)
Figure 45: Type-specific Diagnosed Prevalent Cases of HAE in China (2021-2034)
Figure 46: Gender-specific Diagnosed Prevalent Cases of HAE in China (2021-2034)
Figure 47: Age-specific Diagnosed Prevalent Cases of HAE in China (2021-2034)
Figure 48: Patient Journey of HAE
